Long-term efficacy and safety profile of splenectomy for pediatric chronic immune thrombocytopenia

Int J Hematol. 2023 May;117(5):774-780. doi: 10.1007/s12185-022-03529-z. Epub 2023 Jan 9.

Abstract

There are few reports of the long-term efficacy of splenectomy in children with immune thrombocytopenia (ITP). In a 33-year period, we performed splenectomies in 23 pediatric patients with ITP at a single institution in Japan. The age at surgery was 5-22 years with a median of 10 years. The follow-up period was 1-141 months with a median of 48 months. Before surgery, we confirmed the presence or absence of the accessory spleen by contrast-enhanced CT scan and we recommended vaccination with pneumococcal vaccine. Four patients underwent laparotomy before 1998, and 19 patients underwent laparoscopic surgery after 1999. Splenectomy showed high efficacy with a partial response rate of 83% and a complete response rate of 74%. Complete response was maintained in 70% of patients until the end of the observation period, and 91% were able to discontinue long-term management drugs such as steroids. No serious complications such as infectious diseases were observed. Although the number of cases here was small, the long-term efficacy and safety of splenectomy makes it a viable option in pediatric ITP despite the existence of newer therapeutic agents. Further research is necessary to compare the long-term efficacy and safety of splenectomy with new therapeutic agents.

Keywords: Pediatric ITP; Response rate; Splenectomy; Thrombopoietin receptor agonist.

MeSH terms

  • Adolescent
  • Adult
  • Child
  • Child, Preschool
  • Humans
  • Laparoscopy*
  • Purpura, Thrombocytopenic, Idiopathic* / drug therapy
  • Purpura, Thrombocytopenic, Idiopathic* / surgery
  • Retrospective Studies
  • Splenectomy / adverse effects
  • Steroids / therapeutic use
  • Thrombocytopenia* / drug therapy
  • Treatment Outcome
  • Young Adult

Substances

  • Steroids